表紙:微小残存病変市場:シェア、規模、動向、業界分析レポート、検出標的別、検査技術別、エンドユーザー別、地域別、セグメント別予測、2023年~2032年
市場調査レポート
商品コード
1219535

微小残存病変市場:シェア、規模、動向、業界分析レポート、検出標的別、検査技術別、エンドユーザー別、地域別、セグメント別予測、2023年~2032年

Minimal Residual Disease Market Share, Size, Trends, Industry Analysis Report, By Detection Target (Lymphoma, Leukemia, Solid Tumors, Others); By Test Technique; By End-User; By Region; Segment Forecast, 2023-2032

出版日: | 発行: Polaris Market Research | ページ情報: 英文 119 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
微小残存病変市場:シェア、規模、動向、業界分析レポート、検出標的別、検査技術別、エンドユーザー別、地域別、セグメント別予測、2023年~2032年
出版日: 2023年01月01日
発行: Polaris Market Research
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の微小残存病変の市場規模は、2032年までに71億3,161万米ドルに達すると予測されています。

当レポートでは、世界の微小残存病変市場について調査し、検出標的別、検査技術別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の微小残存病変市場の洞察

  • 微小残存病変- 業界のスナップショット
  • 微小残存病変市場力学
  • ポーターのファイブフォース分析
  • PESTEL分析
  • 微小残存病変市場の業界動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の微小残存病変市場、検出標的別

  • 主な調査結果
  • イントロダクション
    • 世界の微小残存病変市場、検出標的別、2019年~2032年(100万米ドル)
  • リンパ腫
  • 白血病
  • 固形腫瘍
  • その他

第6章 世界の微小残存病変市場、エンドユーザー別

  • 主な調査結果
  • イントロダクション
    • 世界の微小残存病変市場、エンドユーザー別、2019年~2032年(100万米ドル)
  • 病院および専門クリニック
  • 研究所センター

第7章 世界の微小残存病変市場、検査技術別

  • 主な調査結果
  • イントロダクション
    • 世界の微小残存病変市場、検査技術別、2019年~2032年(100万米ドル)
  • フローサイトメトリ
  • ポリメラーゼ連鎖反応(PCR)
  • 次世代シーケンシング(NGS)
  • その他

第8章 世界の微小残存病変市場、地域別

  • 主な調査結果
  • イントロダクション
    • 微小残存病変市場評価、地域別、2019年~2032年(100万米ドル)
  • 微小残存病変市場-北米
  • 微小残存病変市場- 欧州
  • 微小残存病変市場- アジア太平洋
  • 微小残存病変市場-中東・アフリカ
  • 微小残存病変市場-ラテンアメリカ

第9章 競合情勢

第10章 企業プロファイル

  • Sysmex Corporation
  • ArcherDX
  • Adaptive Biotechnologies
  • Natera
  • Inivata
  • Asuragen
  • Guardant Health
  • Cergentis
  • Invivoscribe
  • Mission Bio
  • ARUP Laboratories
  • NeoGenomics Laboratories
  • Bio-Rad Laboratories
  • Opko Health
  • Quest Diagnostics
図表

List of Tables

  • Table 1 Global Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 2 Global Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 3 Global Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 4 Minimal Residual Disease Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 6 North America: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 7 North America: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 8 U.S.: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 9 U.S.: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 10 U.S.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 11 Canada: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 12 Canada: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 13 Canada: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 14 Europe: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 15 Europe: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 16 Europe: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 17 UK: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 18 UK: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 19 UK: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 20 France: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 21 France: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 22 France: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 23 Germany: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 24 Germany: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 25 Germany: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 26 Italy: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 27 Italy: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 28 Italy: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 29 Spain: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 30 Spain: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 31 Spain: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 32 Netherlands: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 33 Netherlands: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 34 Netherlands: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 35 Russia: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 36 Russia: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 37 Russia: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 41 China: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 42 China: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 43 China: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 44 India: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 45 India: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 46 India: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 47 Malaysia: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 48 Malaysia: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 49 Malaysia: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 50 Japan: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 51 Japan: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 52 Japan: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 53 Indonesia: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 54 Indonesia: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 55 Indonesia: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 56 South Korea: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 57 South Korea: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 58 South Korea: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 65 UAE: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 66 UAE: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 67 UAE: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 68 Israel: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 69 Israel: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 70 Israel: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 71 South Africa: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 72 South Africa: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 73 South Africa: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 74 Latin America: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 75 Latin America: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 76 Latin America: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 77 Mexico: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 78 Mexico: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 79 Mexico: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 80 Brazil: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 81 Brazil: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 82 Brazil: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • Table 83 Argentina: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • Table 84 Argentina: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • Table 85 Argentina: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Minimal Residual Disease Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by End-User
  • Figure 7. Global Minimal Residual Disease Market, by End-User, 2021 & 2030 (USD Million)
  • Figure 8. Market by Detection Target
  • Figure 9. Global Minimal Residual Disease Market, by Detection Target, 2021 & 2030 (USD Million)
  • Figure 10. Market by Test Technique
  • Figure 11. Global Minimal Residual Disease Market, by Test Technique, 2021 & 2030 (USD Million)
  • Figure 12. Minimal Residual Disease Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Minimal Residual Disease Market
目次
Product Code: PM2988

The global minimal residual disease market size is expected to reach USD 7,131.61 million by 2032, according to a new study by Polaris Market Research. The report "Minimal Residual Disease Market Share, Size, Trends, Industry Analysis Report, By Detection Target (Lymphoma, Leukemia, Solid Tumors, Others); By Test Technique; By End-Use; By Region; Segment Forecast, 2023-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increased prevalence of hematological malignancy and cancer, as well as rising healthcare spending, are expected to drive growth in the minimal residual disease sector throughout the forecast period. Additionally, rising consumer awareness of customized therapy and expanding investments in MRD research by public and private entities are both assisting in the market's expansion. Growth in the market is being slowed down by the heavy price of R&D activities.

The appropriate clinical evidence is used to successfully manage cancer therapies to prevent a residue of tumorous cells, and they are also tailored based on unique progression profiles in each individual. The necessity to consider a patient's unique genetic traits in order to provide effective therapy is being driven by several research studies. For example, in October 2022, Adaptive Biotechnologies, a commercial-stage biotechnology firm aiming to transform the genetics of the adaptive immune system into therapeutic solutions to detect and cure disease, announced a partnership with Epic to substantiate clonoSEQ Assay into Epic's full EMR system.

Additionally, the rising number of cancer patients and the rise in R&D spending are the two main factors driving the market. In addition, the industry is expanding due to the growing use of next-generation sequencing technologies. Additionally, the technological developments in diagnostics and therapies brought about by rising R&D expenditures are what's fueling the market's expansion.

Globally, the COVID-19 pandemic had an impact on healthcare systems and caused many healthcare facilities to stop providing routine care, putting at-risk cancer patients at serious risk. Although since the outbreak of the COVID-19 pandemic, steps have been taken to increase the number of covid patients admitted and decrease the number of non-covid patients admitted, resulting in treatment delays.

Minimal Residual Disease Market Report Highlights

  • In 2022, leukemia will dominate the market. The primary growth of the market is due to the fact that one person is diagnosed with leukemia every three minutes in the United States.
  • In 2022, flow cytometry is dominating the market due to the high sensitivity and broad applicability of MRD testing enabled by flow cytometry.
  • The industry sector with the largest revenue share in 2022 was hospitals and specialty clinics. The main factor driving the market is the availability of professionals in hospitals who can help patients choose pertinent MRD tests.
  • In 2022, North America is dominating the market of minimal residual disease due to the rising number of patients in the United States.
  • The global players with a global presence include Invivoscribe, NeoGenomics Laboratories, Bio-Rad Laboratories, Opko Health, Adaptive Biotechnologies, Natera, Inivata, Sysmex Corporation, and Quest Diagnostics.

Polaris Market Research has segmented the Minimal Residual Disease Market report based on detection target, test technique, end-user, and region:

Minimal Residual Disease, Detection Target Outlook (Revenue - USD Million, 2019 - 2032)

  • Lymphoma
  • Leukemia
  • Solid Tumors
  • Others

Minimal Residual Disease, Test Technique Outlook (Revenue - USD Million, 2019 - 2032)

  • Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Next Generation Sequencing (NGS)
  • Others

Minimal Residual Disease, End-User Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospitals and Specialty Clinics
  • Laboratory Centers

Minimal Residual Disease, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Minimal Residual Disease Market Insights

  • 4.1. Minimal Residual Disease - Industry Snapshot
  • 4.2. Minimal Residual Disease Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Prevalence Of Cancer
      • 4.2.1.2. Growing Investment For Research
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High-Cost Associated With Mrd Testing
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Minimal Residual Disease Market Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Minimal Residual Disease Market, by Detection Target

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
  • 5.3. Lymphoma
    • 5.3.1. Global Minimal Residual Disease Market, by Lymphoma, by Region, 2019-2032 (USD Million)
  • 5.4. Leukemia
    • 5.4.1. Global Minimal Residual Disease Market, by Leukemia, by Region, 2019-2032 (USD Million)
  • 5.5. Solid Tumors
    • 5.5.1. Global Minimal Residual Disease Market, by Solid Tumors, by Region, 2019-2032 (USD Million)
  • 5.6. Others
    • 5.6.1. Global Minimal Residual Disease Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Minimal Residual Disease Market, by End-User

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • 6.3. Hospitals and Specialty Clinics
    • 6.3.1. Global Minimal Residual Disease Market, by Hospitals and Specialty Clinics, by Region, 2019-2032 (USD Million)
  • 6.4. Laboratory Centres
    • 6.4.1. Global Minimal Residual Disease Market, by Laboratory Centres, by Region, 2019-2032 (USD Million)

7. Global Minimal Residual Disease Market, by Test Technique

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
  • 7.3. Flow Cytometry
    • 7.3.1. Global Minimal Residual Disease Market, by Flow Cytometry, by Region, 2019-2032 (USD Million)
  • 7.4. Polymerase Chain Reaction (PCR)
    • 7.4.1. Global Minimal Residual Disease Market, by Polymerase Chain Reaction (PCR), by Region, 2019-2032 (USD Million)
  • 7.5. Next Generation Sequencing (NGS)
    • 7.5.1. Global Minimal Residual Disease Market, by Next Generation Sequencing (NGS), by Region, 2019-2032 (USD Million)
  • 7.6. Others
    • 7.6.1. Global Minimal Residual Disease Market, by Others, by Region, 2019-2032 (USD Million)

8. Global Minimal Residual Disease Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Minimal Residual Disease Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Minimal Residual Disease Market - North America
    • 8.3.1. North America: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
    • 8.3.2. North America: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
    • 8.3.3. North America: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.3.4. Minimal Residual Disease Market - U.S.
      • 8.3.4.1. U.S.: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.3.5. Minimal Residual Disease Market - Canada
      • 8.3.5.1. Canada: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • 8.4. Minimal Residual Disease Market - Europe
    • 8.4.1. Europe: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
    • 8.4.3. Europe: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.4.4. Minimal Residual Disease Market - UK
      • 8.4.4.1. UK: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.4.5. Minimal Residual Disease Market - France
      • 8.4.5.1. France: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.4.5.3. France: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.4.6. Minimal Residual Disease Market - Germany
      • 8.4.6.1. Germany: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.4.7. Minimal Residual Disease Market - Italy
      • 8.4.7.1. Italy: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.4.8. Minimal Residual Disease Market - Spain
      • 8.4.8.1. Spain: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.4.9. Minimal Residual Disease Market - Netherlands
      • 8.4.9.1. Netherlands: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.4.10. Minimal Residual Disease Market - Russia
      • 8.4.10.1. Russia: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • 8.5. Minimal Residual Disease Market - Asia Pacific
    • 8.5.1. Asia Pacific: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.5.4. Minimal Residual Disease Market - China
      • 8.5.4.1. China: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.5.4.3. China: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.5.5. Minimal Residual Disease Market - India
      • 8.5.5.1. India: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.5.5.3. India: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.5.6. Minimal Residual Disease Market - Malaysia
      • 8.5.6.1. Malaysia: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.5.7. Minimal Residual Disease Market - Japan
      • 8.5.7.1. Japan: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.5.8. Minimal Residual Disease Market - Indonesia
      • 8.5.8.1. Indonesia: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.5.9. Minimal Residual Disease Market - South Korea
      • 8.5.9.1. South Korea: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • 8.6. Minimal Residual Disease Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.6.4. Minimal Residual Disease Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.6.5. Minimal Residual Disease Market - UAE
      • 8.6.5.1. UAE: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.6.6. Minimal Residual Disease Market - Israel
      • 8.6.6.1. Israel: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.6.7. Minimal Residual Disease Market - South Africa
      • 8.6.7.1. South Africa: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
  • 8.7. Minimal Residual Disease Market - Latin America
    • 8.7.1. Latin America: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.7.4. Minimal Residual Disease Market - Mexico
      • 8.7.4.1. Mexico: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.7.5. Minimal Residual Disease Market - Brazil
      • 8.7.5.1. Brazil: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)
    • 8.7.6. Minimal Residual Disease Market - Argentina
      • 8.7.6.1. Argentina: Minimal Residual Disease Market, by Detection Target, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Minimal Residual Disease Market, by Test Technique, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Minimal Residual Disease Market, by End-User, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Sysmex Corporation
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Detection Target Benchmarking
    • 10.1.4. Recent Development
  • 10.2. ArcherDX
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Detection Target Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Adaptive Biotechnologies
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Detection Target Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Natera
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Detection Target Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Inivata
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Detection Target Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Asuragen
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Detection Target Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Guardant Health
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Detection Target Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Cergentis
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Detection Target Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Invivoscribe
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Detection Target Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Mission Bio
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Detection Target Benchmarking
    • 10.10.4. Recent Development
  • 10.11. ARUP Laboratories
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Detection Target Benchmarking
    • 10.11.4. Recent Development
  • 10.12. NeoGenomics Laboratories
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Detection Target Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Bio-Rad Laboratories
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Detection Target Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Opko Health
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Detection Target Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Quest Diagnostics
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Detection Target Benchmarking
    • 10.15.4. Recent Development